Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.

PloS one - 1 Jan 2017

Koeppel Florence, Blanchard Steven, Jovelet Cécile, Genin Bérengère, Marcaillou Charles, Martin Emmanuel, Rouleau Etienne, Solary Eric, Soria Jean-Charles, André Fabrice, Lacroix Ludovic

Abstract excerpt

Tumor mutation load (TML) has been proposed as a biomarker of patient response to immunotherapy in several studies. TML is usually determined by tumor biopsy DNA (tDNA) whole exome sequencing (WES), therefore TML evaluation is limited by informative biopsy availability. Circulating cell free DNA (cfDNA) provided by liquid biopsy is a surrogate specimen to biopsy for molecular profiling. Nevertheless performing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Exome Sequencing

Share to Liquid Biopsy

Share to Mutation

Share to Mutation Rate

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29161279
DOI: 10.1371/journal.pone.0188174
PMCID: PMC5697854

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.PMID 29161279Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.Semantic proximity Read ↗

Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in CancerSemantic proximity Read ↗

Concordance between whole exome sequencing of circulating tumor DNA and tumor tissue.Semantic proximity Read ↗

Liquid biopsy: current technology and clinical applicationsSemantic proximity Read ↗

Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.Semantic proximity Read ↗

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.Semantic proximity Read ↗

Clinical Applications of Next-Generation Sequencing in Precision OncologySemantic proximity Read ↗

Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities.Semantic proximity Read ↗

Liquid biopsy and its role in an advanced clinical trial for lung cancer.Semantic proximity Read ↗

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read ↗

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.